- Home
- PD vs AVTX Comparison
PD vs AVTX Comparison
Compare PD & AVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PD | AVTX |
|---|---|---|
| Founded | 2009 | 2011 |
| Country | United States | United States |
| Employees | 1155 | 33 |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 888.6M |
| IPO Year | 2019 | 2015 |
Fundamental Metrics
Financial Performance| Metric | PD | AVTX |
|---|---|---|
| Price | $14.41 | $16.10 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 8 |
| Target Price | $12.63 | ★ $40.57 |
| AVG Volume (30 Days) | ★ 1.5M | 874.4K |
| Earning Date | 05-28-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 416.95 | 72.07 |
| EPS | ★ 0.19 | N/A |
| Revenue | ★ $492,546,000.00 | $27,813,137.00 |
| Revenue This Year | $3.58 | N/A |
| Revenue Next Year | $2.88 | N/A |
| P/E Ratio | $73.53 | ★ N/A |
| Revenue Growth | 5.36 | ★ 2312.27 |
| 52 Week Low | $5.70 | $10.70 |
| 52 Week High | $16.91 | $24.27 |
Technical Indicators
Market Signals| Indicator | PD | AVTX |
|---|---|---|
| Relative Strength Index (RSI) | 62.55 | 35.14 |
| Support Level | $12.78 | $15.24 |
| Resistance Level | $14.43 | $16.80 |
| Average True Range (ATR) | 0.48 | 1.02 |
| MACD | -0.06 | -0.27 |
| Stochastic Oscillator | 68.95 | 14.12 |
Price Performance
Historical ComparisonAbout PD PagerDuty Inc.
PagerDuty Inc is a digital operations management platform that manages urgent and mission-critical work for a modern, digital business. Its PagerDuty Operations Cloud combines artificial intelligence (AI) operations (AIOps), automation, customer service operations, and incident management with a generative AI assistant to create a flexible, resilient, and scalable platform to protect revenue and improve customer experience, improve operational efficiency, and mitigate the risk of operational failures. The company generates revenue predominantly from cloud-hosted software subscription fees and term-license software subscription fees. Geographically, the company derives a majority of its revenue from the United States and the rest from International markets.
About AVTX Avalo Therapeutics Inc.
Avalo Therapeutics Inc is a clinical stage biotechnology company fully dedicated to developing IL-1B-based treatments for immune-mediated inflammatory diseases. The company's asset is Abdakibart (AVTX-009) an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalos pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein), AVTX-006 and AVTX-913.